井上 義一 いのうえ よしかず 先生

来歴等

略歴

1983年 愛媛大学医学部 卒業
1983年 愛媛大学医学部 第二内科
1984年 愛媛大学医学部 医学研究科 博士課程
1988年 愛媛大学医学部 医学研究科 博士課程 修了
1988年 国立療養所 愛媛病院 内科 呼吸器科
1991年 愛媛大学医学部附属病院 第二内科 助手
1994年 米国コロラド大学関連 National Jewish Center for Immunology and Respiratory Medicine 留学
1997年 国立療養所 近畿中央病院内科 医長
1998年 国立療養所 近畿中央病院 臨床研究部免疫研究室室長（内科医長兼任）
2001年 国立療養所 近畿中央病院 臨床研究センター 呼吸不全研究部長
2004年 国立病院機構 近畿中央胸部疾患センター 臨床研究センター 呼吸不全難治性肺疾患研究部長
2006年 大阪大学医学系研究科連携大学院 腫瘍感染免疫学 招聘助教授
2011年 大阪大学大学院医学系研究科連携大学院腫瘍感染免疫学 招聘教授（現職）
2014年 国立病院機構 近畿中央胸部疾患センター 臨床研究センター長
2018年 国立病院機構 近畿中央呼吸器センター 臨床研究センター長（現職）
2023年 大阪府結核予防会大阪複十字病院 顧問
2023年 国立病院機構近畿中央呼吸器センター臨床研究センター 客員研究員

もっと見る

論文

• 1. IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med. 2020 Oct 22;383(17):1635-1644

  Trapnell BC, Inoue Y, Bonella F, Morgan C, Jouneau S, Bendstrup E, Campo I, Papiris SA, Yamaguchi E, Cetinkaya E, Ilkovich MM, Kramer MR, Veltkamp M, Kreuter M, Baba T, Ganslandt C, Tarnow I, Waterer G, Jouhikainen T

• 2.Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69

  Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC.

• 3.Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. Orphanet J Rare Dis. 2020 Sep 29;15(1):272

  Katayama K, Hirose M, Arai T, Hatsuda K, Tachibana K, Sugawara R, Sugimoto C, Kasai T, Akira M, Inoue Y.

• 4.Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. J Thorac Dis. 2020 Aug;12(8):4132-4147

  Arai T, Akira M, Sugimoto C, Tachibana K, Inoue Y, Shintani S, Okuma T, Kasai T, Hayashi S, Inoue Y.

• 5.Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. Curr Opin Pulm Med. 2020 Sep;26(5):507-517.

  Yanagihara T, Inoue Y.

• 6.Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020 Jul;8(7):726-737.

  Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San Jos? Est?par R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA.

• 7.Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. Intern Med. 2020 Oct 15;59(20):2539-2546

  Arai T, Kasai T, Shimizu K, Kawahara K, Katayama K, Sugimoto C, Hirose M, Okamoto H, Tachibana K, Akira M, Inoue Y.

• 8.Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res. 2020 May 26;6(2):00184-2019

  Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, Inoue Y, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y.

• 9.Serum immunoglobulin a antibodies to glycopeptidolipid core antigen for Mycobacteroides abscessus complex lung disease. Int J Mycobacteriol. 2020 Jan-Mar;9(1):76-82

  Kobayashi T, Tsuyuguchi K, Yoshida S, Kurahara Y, Minomo S, Inoue Y, Suzuki K.

• 10.Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020 May;7(1):e000558.

  Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y.

• 11.Is corticosteroid use truly not associated with improved outcomes in AE-IPF? Respirology. 2020 Jun;25(6):659

  Arai T, Inoue Y.

• 12.Two New Cases of Pulmonary Infection by Mycobacterium shigaense, Japan. Emerg Infect Dis. 2020 Nov;26(11):2728-2732

  Yoshida S, Iwamoto T, Kobayashi T, Nomoto R, Inoue Y, Tsuyuguchi K, Suzuki K.

• 13.Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient. J Antimicrob Chemother. 2020 Jul 1;75(7):1722-1725

  Yoshida S, Iwamoto T, Arikawa K, Sekizuka T, Kuroda M, Inoue Y, Mitarai S, Tsuji T, Tsuyuguchi K, Suzuki K.

• 14.Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. Respir Investig. 2020 Jul;58(4):262-268

  Minomo S, Arai T, Higo H, Tsuji T, Tachibana K, Akira M, Inoue Y.

• 15.The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. Chest. 2020 Jul;158(1):106-116.

  Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN.

• 16.Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest. 2020 Aug;158(2):646-659

  Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK.

• 17.The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology. 2020 Jul;296(1):172-180

  Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin O, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN.

• 18.Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020 May;8(5):453-460

  Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators.

• 19.Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation. Respirol Case Rep. 2020 Feb 20;8(3):e00541.

  Inagaki Y, Tachibana K, Inoue Y, Kasai T, Inoue Y.

• 20.High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. Jpn J Radiol. 2020 Jun;38(6):524-532

  Tateishi T, Johkoh T, Sakai F, Miyazaki Y, Ogura T, Ichikado K, Suda T, Taguchi Y, Inoue Y, Takemura T, Colby TV, Sumikawa H, Fujimoto K, Arakawa H, Raoof S, Inase N.

• 21.Validation of a new serum granulocyte-macrophage colony-stimulating factor autoantibody testing kit. ERJ Open Res. 2020 Jan 27;6(1):00259-2019.

  Nakata K, Sugi T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, Ueda T, Aoki A, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Hirano T, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T, Tanaka T, Mikami A, Kitamura N.

• 22.MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight. 2020 Feb 27;5(4):e132048

  Liu H, Osterburg AR, Flury J, Swank Z, McGraw DW, Gupta N, Wikenheiser-Brokamp KA, Kumar A, Tazi A, Inoue Y, Hirose M, McCormack FX, Borchers MT.

• 23.Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2993-3002.

  Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P.

• 24.Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2979-2991.

  Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.

• 25.Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med. 2020 May 1;201(9):1110-1119.

  Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S.

• 26.Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis. Respirology. 2020 Jan;25(1):20-22.

  Varone F, Inoue Y, Richeldi L.

• 27.Morphine for dyspnoea in chronic obstructive pulmonary disease: a before-after efficacy study. BMJ Support Palliat Care. 2019 Nov 15:bmjspcare-2019-001929.

  Matsuda Y, Morita T, Matsumoto H, Hosoi K, Kusama K, Kohashi Y, Morishita H, Kaku S, Ariyoshi K, Oyamada S, Inoue Y, Iwase S, Yamaguchi T, Nishikawa M.

• 28.Airway-centered Fibroelastosis Accompanied by Subpleural Lesions of Unknown Cause in a Young Man Who Later Developed Pulmonary Hypertension. Intern Med. 2020 Mar 1;59(5):695-700

  Minomo S, Arai T, Tachibana K, Matsui H, Kasai T, Akira M, Inoue Y.

• 29. INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727.

  Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK

• 30.Study Group of Diffuse Interstitial Lung Disease in Japan. Inter-observer agreement in identifying traction bronchiectasis on computed tomography: its improvement with the use of the additional criteria for chronic fibrosing interstitial pneumonia. Jpn J Radiol. 2019 Nov;37(11):773-780

  Tominaga J, Bankier AA, Lee KS, Leung AN, Remy-Jardin M, Akira M, Arakawa H, Boiselle PM, Franquet T, Fujimoto K, Gevenois PA, Goo JM, Grenier PA, Hatabu H, Ichikado K, Im JG, Johkoh T, Lee KN, Lynch DA, Noma S, Song JW, Sakai F, Sugiyama Y

• 31.Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019 Sep 5;381(10):923-932.

  Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K.

• 32.DLD/TO Assemblies of JRS. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig. 2019 Nov;57(6):512-533

  Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K

• 33.Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS?-ON. Respirology. 2020 Apr;25(4):410-416

  Song JW, Ogura T, Inoue Y, Xu Z, Quaresma M, Stowasser S, Stansen W, Crestani B.

• 34.INMARK trial investigators.Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019 Sep;7(9):771-779.

  Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG

• 35.Antimicrobial susceptibility patterns and MICs among non-photochromogenic rapidly growing Mycobacteroides and Mycolicibacterium species. J Med Microbiol. 2019 Sep;68(9):1279-1286

  Yoshida S, Tsuyuguchi K, Chikamatsu K, Aono A, Takaki A, Mitarai S, Kobayashi T, Inoue Y, Suzuki K.

• 36.Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol. BMJ Open Respir Res. 2019 May 30;6(1):e000434.

  Nakagawa T, Hashimoto H, Yagi M, Kogure Y, Sekimizu M, Saito AM, Ogawa K, Inoue Y.

• 37.Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153.

  Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

• 38.Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019 Mar 25;6(1):e000397

  Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L.

• 39.GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019 Sep 12;381(11):1023-1034

  Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ram?rez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ

• 40.Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep. 2019 May 14;9(1):7355

  Enomoto N, Egashira R, Tabata K, Hashisako M, Kitani M, Waseda Y, Ishizuka T, Watanabe S, Kasahara K, Izumi S, Shiraki A, Miyamoto A, Kishi K, Kishaba T, Sugimoto C, Inoue Y, Kataoka K, Kondoh Y, Tsuchiya Y, Baba T, Sugiura H, Tanaka T, Sumikawa H, Suda T.

• 41.Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208

  Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Va??kov? M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

• 42.Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases in Japan. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal. Respir Investig. 2019 Jul;57(4):312-320

  Watanabe K, Ishii H, Kiyomi F, Terasaki Y, Hebisawa A, Kawabata Y, Johkoh T, Sakai F, Kondoh Y, Inoue Y, Azuma A, Suda T, Ogura T, Inase N, Homma S

• 43.Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J. 2019 May 18;53(5):1802243

  Fujisawa T, Mori K, Mikamo M, Ohno T, Kataoka K, Sugimoto C, Kitamura H, Enomoto N, Egashira R, Sumikawa H, Iwasawa T, Matsushita S, Sugiura H, Hashisako M, Tanaka T, Terasaki Y, Kunugi S, Kitani M, Okuda R, Horiike Y, Enomoto Y, Yasui H, Hozumi H, Suzuki Y, Nakamura Y, Fukuoka J, Johkoh T, Kondoh Y, Ogura T, Inoue Y, Hasegawa Y, Inase N, Homma S, Suda T.

• 44.NIH Rare Lung Disease Consortium. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019 Apr 4;53(4):1802066

  Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX

• 45.Osaka Acute Exacerbation of Interstitial Pneumonia Research Group. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2019 Jul;24(7):658-666

  Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Edahiro R, Hamasaki T, Inoue Y

• 46.Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One. 2019 Feb 28;14(2):e0212776.

  Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, Young LR, McCormack FX, Inoue Y.

• 47.Lung function outcomes in the INPULSIS? trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019 Jan;146:42-48

  Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

• 48.Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 21;27(150):180075

  Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y.

• 49.Pulmonary Veno-occlusive Disease: A Surgical Lung Biopsy-proven and Autopsied Case Radiologically Mimicking Hypersensitivity Pneumonitis at the Time of a Transbronchial Lung Biopsy. Intern Med. 2019 Apr 1;58(7):955-964

  Minomo S, Kitaichi M, Arai T, Matsui H, Akira M, Inoue Y.

• 50.Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. Intern Med. 2019 Feb 15;58(4):569-574

  Sonobe S, Arai T, Tanimoto Y, Sugimoto C, Kitaichi M, Akira M, Kasai T, Hirose M, Inoue Y.

もっと見る

著書

• 1.McCormack FX, Inoue Y. Lymphangioleiomyomatosis. Murray & Nadel’s textbook of respiratory medicine. 6th Ed (Vol.2). Mason RJ, Brnse J, King TEJ, et al. Broaddus VC, MartinTR, et al ed.. Saunders Elsevier, p1243-1259, 2015

• 2.Trapnell BC, Nakata K, Inoue Y. Autoimmune pulmonary alveolar proteinosis. Molecular Basis of Pulmonary Disease Insights from Rare Lung Disorders. p.111-132. Humana Press, Springer New York Dordrecht Heidelberg London. Edited by Francis X. McCormack, MD, Ralph J. Panos, MD, Bruce C. Trapnell, MD, 2010

もっと見る

受賞

• 2015年 Scientific Advancement Award受賞, The LAM Foundation (Chicago)

その他

• 【患者会・社会活動】2001年 J-LAMの会（リンパ脈管筋腫症患者と支援者の会）医療アドバイザー（現）

• 【患者会・社会活動】2004年 The Pulmonary Alveolar Proteinosis Foundation Clinical Advisory Board（現）

• 【患者会・社会活動】2007年 The LAM Foundation Clinical Science Board

• 【患者会・社会活動】2010年 日本肺胞蛋白症患者会　顧問（現）

• 【患者会・社会活動】2014年 The LAM Foundation Scientific Advisory Board（現）

• 【患者会・社会活動】LAM Clinic, Clinical director（現）

• 【患者会・社会活動】厚労科研難治性疾患政策研究事業、びまん性肺疾患に関する調査研究班、疾病の普及・啓発・患者会支援部会部会長